227 related articles for article (PubMed ID: 32110554)
1. Experimental Study of Hepatocellular Carcinoma Treatment by Shikonin Through Regulating PKM2.
Liu T; Li S; Wu L; Yu Q; Li J; Feng J; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
J Hepatocell Carcinoma; 2020; 7():19-31. PubMed ID: 32110554
[TBL] [Abstract][Full Text] [Related]
2. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
3. PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma.
Feng J; Wu L; Ji J; Chen K; Yu Q; Zhang J; Chen J; Mao Y; Wang F; Dai W; Xu L; Wu J; Guo C
J Exp Clin Cancer Res; 2019 May; 38(1):204. PubMed ID: 31101057
[TBL] [Abstract][Full Text] [Related]
4. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
5. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation.
Zhang Q; Liu Q; Zheng S; Liu T; Yang L; Han X; Lu X
J Cancer; 2021; 12(16):4830-4840. PubMed ID: 34234853
[No Abstract] [Full Text] [Related]
6. [Shikonin induces hepatocellular carcinoma cell apoptosis by suppressing PKM2/PHD3/HIF-1
Zhang H; Chen Z; Zhao X; Huo Q; Cheng X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):92-98. PubMed ID: 36856215
[TBL] [Abstract][Full Text] [Related]
7. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
8. HSP90 promotes cell glycolysis, proliferation and inhibits apoptosis by regulating PKM2 abundance via Thr-328 phosphorylation in hepatocellular carcinoma.
Xu Q; Tu J; Dou C; Zhang J; Yang L; Liu X; Lei K; Liu Z; Wang Y; Li L; Bao H; Wang J; Tu K
Mol Cancer; 2017 Dec; 16(1):178. PubMed ID: 29262861
[TBL] [Abstract][Full Text] [Related]
9. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Shikonin against Esophageal Cancer Cells and its possible mechanisms
Tang JC; Zhao J; Long F; Chen JY; Mu B; Jiang Z; Ren Y; Yang J
J Cancer; 2018; 9(1):32-40. PubMed ID: 29290767
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma.
Lu J; Liu SY; Zhang J; Yang GM; Gao GB; Yu NN; Li YP; Li YX; Ma ZQ; Wang Y; Lu CH
Am J Cancer Res; 2021; 11(7):3575-3593. PubMed ID: 34354861
[TBL] [Abstract][Full Text] [Related]
13. GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism.
Zhou Q; Yin Y; Yu M; Gao D; Sun J; Yang Z; Weng J; Chen W; Atyah M; Shen Y; Ye Q; Li CW; Hung MC; Dong Q; Zhou C; Ren N
Redox Biol; 2022 Oct; 56():102458. PubMed ID: 36116159
[TBL] [Abstract][Full Text] [Related]
14. Shikonin ameliorated mice colitis by inhibiting dimerization and tetramerization of PKM2 in macrophages.
Huang B; Wang Q; Jiang L; Lu S; Li C; Xu C; Wang C; Zhang E; Zhang X
Front Pharmacol; 2022; 13():926945. PubMed ID: 36059938
[TBL] [Abstract][Full Text] [Related]
15. Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway.
Zhang J; Zhou J; Xiao S
Anticancer Drugs; 2020 Oct; 31(9):932-941. PubMed ID: 32282369
[TBL] [Abstract][Full Text] [Related]
16. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
Li W; Liu J; Zhao Y
Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Inhibition of Ornithine Decarboxylase 1 and Pyruvate Kinase M2 Exerts Synergistic Effects Against Hepatocellular Carcinoma Cells.
Zeng Z; Lan J; Lei S; Yang Y; He Z; Xue Y; Chen T
Onco Targets Ther; 2020; 13():11697-11709. PubMed ID: 33244237
[TBL] [Abstract][Full Text] [Related]
18. Dauricine upregulates the chemosensitivity of hepatocellular carcinoma cells: Role of repressing glycolysis via miR-199a:HK2/PKM2 modulation.
Li W; Qiu Y; Hao J; Zhao C; Deng X; Shu G
Food Chem Toxicol; 2018 Nov; 121():156-165. PubMed ID: 30171973
[TBL] [Abstract][Full Text] [Related]
19. Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/SMAD7/TGF-β signaling pathway.
Li X; Zeng X
Cell Biol Int; 2020 Feb; 44(2):467-476. PubMed ID: 31617643
[TBL] [Abstract][Full Text] [Related]
20. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
